Rich Pharmaceuticals, Inc. Stock Price - RCHA

Best deals to access real time data!
SMALL CAP PRO
Monthly Subscription
for only
$44.59
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$31.00
SMALL CAP BASIC
Monthly Subscription
for only
$30.03
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Rich Pharmaceuticals, Inc. (PC) RCHA Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0 +0% 0.0005 0.0005 0.0005 0.0005 0.0005 08:15:50
Bid Price Ask Price Spread Spread % News
0.0004 0.0005 0.0001 20.00% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1 100,000 $ 0.0005 $ 50 18.46M 0.0000 - 0.0078
Last Trade Time Type Quantity Stock Price Currency
09:30:06 100,000 $0.00 USD

Rich Pharmaceuticals, Inc. (PC) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 477.51k 955.03M $ -3.24M - -0.15 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Rich Pharmaceuticals, Inc. (PC) News

Latest RCHA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RCHA Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.00040.00050.0003950.00053M19M13M0.000125.00%
1 Month0.00040.00070.0003950.00062M42M13M0.000125.00%
3 Months0.00060.000880.0003950.0006660k134M13M-0.0001-16.67%
6 Months0.00250.00270.0003950.0009660k274M31M-0.002-80.00%
1 Year0.00010.00780.000010.00070829M48M0.0004400.00%
3 Years0.001540.0190.0000010.000802B54M-0.00104-67.53%
5 Years0.220.4550.0000010.001002B39M-0.2195-99.77%

Rich Pharmaceuticals, Inc. (PC) Description

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.